PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Reynold A. Panettieri, Jr., MD - Improving Adherence to Evidence-Based Guidelines for the Diagnosis and Management of COPD: Practical Strategies for the Healthcare Team to Optimize Patient Care
Go online to PeerView.com/NBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in COPD discusses evidence-based guidelines to diagnose and treat COPD, as well as multidisciplinary strategies to increase adherence to treatment. Upon completion of this activity, participants will be able to: Employ evidence-based guidelines to diagnose patients with chronic obstructive pulmonary disease (COPD), Create treatment plans for patients with COPD according to evidence-based guidelines to minimize exacerbation risk, preserve lung function, and improve quality of life, Discuss opportunities for members of the healthcare team to improve care for patients with COPD and minimize time constraints on primary care physicians, Apply strategies for patients to become more engaged in their care to improve adherence to treatment regimens.
Axel Grothey, MD - Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies
Go online to PeerView.com/PXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status, Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection, Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others, Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences.
Manish A. Shah, MD, FASCO - Checkpoint Inhibition in Gastrointestinal Cancers: Recent Advances in Gastric, Esophageal, and Colorectal Cancers and Their Application in Clinical Practice
Go online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice. Upon completion of this activity, participants should be better able to: Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers, Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers, Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers, Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers.
Jacob Sands, MD - Selective Inhibition of Oncogenic Transcription and Other Novel Approaches in the Treatment of Small Cell Lung Cancer: An Illustrative Guide to Navigating the Evolving Treatment Landscape and Integrating Latest Treatment Modalities Int
Go online to PeerView.com/JCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in small cell lung cancer provides an overview of the features and challenges associated with the condition, as well as the current treatment landscape. Upon completion of this activity, participants should be better able to: Describe the current recommendations for diagnosis, staging, and appropriate evaluation of patients with SCLC throughout the disease course, Characterize the mechanisms of action and rationale for use of new/emerging therapies, including novel transcription inhibitors, for SCLC, Analyze the efficacy and safety data from the latest clinical trials evaluating standard, new, and emerging systemic therapies for SCLC, Integrate latest therapies into individualized treatment plans for appropriate patients with SCLC in the setting of clinical practice or clinical trial participation.
Anne H. Cross, MD, FAAN / Prof. Xavier Montalban - Exploring the Rationale, Results, and Real-World Clinical Potential of BTK Inhibitors in the Management of Multiple Sclerosis
Go online to PeerView.com/BTV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple sclerosis (MS) is associated with complex pathophysiology and numerous management challenges, resulting in the need for a full and diverse range of treatment options. Bruton tyrosine kinase (BTK) inhibitors hinder actions of B cells and resident CNS innate immune cells (microglia) that can contribute to neuroinflammation and neurodegeneration and ultimately lead to disease progression and disability. Based on these mechanisms, BTK inhibitors have the potential to improve outcomes related to inflammation and neurodegeneration. In this PeerView educational activity based on a recent live web broadcast, our experts offer insights into the rationale for using BTK inhibitors to treat MS, current evidence regarding the use of BTK inhibitors in the treatment of MS, and the potential role of BTK inhibitors for individualized MS management based on available evidence and patient characteristics. Upon completion of this activity, participants should be better able to: Recognize the rationale for using Bruton tyrosine kinase (BTK) inhibitors to treat multiple sclerosis (MS), Summarize current evidence regarding the use of BTK inhibitors in the treatment of MS, Assess the potential role of BTK inhibitors for individualized MS management based on available evidence and patient characteristics.
Professor Kausik Ray - Mastering the Management of Hyperlipidemia in Statin-Treated or Statin-Intolerant Patients: Recent Treatment Advances for Patients That Remain at High Risk of ASCVD
Go online to PeerView.com/ZWU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with atherosclerotic cardiovascular disease (ASCVD) are at high risk for future CV events. Hence, interventions such as lowering levels of low-density lipoprotein cholesterol (LDL-C) are indicated for reducing the risk of CV events and, in some populations, to reduce all-cause mortality. Despite the availability of national guidelines to inform the safe and effective use of lipid-lowering therapies, many patients with high-risk ASCVD fail to achieve their targeted LDL-C levels, especially in statin-treated or statin-intolerant high-risk patient populations. At a recent live web broadcast, a multidisciplinary panel of experts discussed the current perspectives and guidelines on hyperlipidemia management, explored the emerging role of newer nonstatin therapies including PCSK9-targeting agents, and gave practical insights on the possible use of these novel lipid-lowering agents to manage hyperlipidemia in high-risk patients with ASCVD. If you couldn't watch the live event, catch up with this on-demand version now! Upon completion of this activity, participants will be able to:Summarize recommendations offered in current treatment guidelines for the management of hyperlipidemia, both for primary and secondary prevention of cardiovascular events in patients with ASCVD, Assess available efficacy and safety data for current and emerging non-statin lipid-lowering agents in the setting of ASCVD, especially in patients on maximally tolerated doses of statin or statin-intolerant patients, Describe the mechanisms of action for newer lipid-lowering therapies to optimize treatment for patients on maximally tolerated doses of statin or statin-intolerant patients, Incorporate newer lipid-lowering therapies, alone or in combination, as appropriate, to provide guideline-directed LDL-C reduction and cardiovascular risk reduction in patients with high-risk ASCVD.